ホーム>>Infectious Disease>> Viral Diseases>>Ganciclovir-d5

Ganciclovir-d5 (Synonyms: 2’-Nor-2’-deoxyguanosine-d5)

カタログ番号GC47391

ガンシクロビルの定量化のための内部標準

Products are for research use only. Not for human use. We do not sell to patients.

Ganciclovir-d5 化学構造

Cas No.: 1189966-73-1

サイズ 価格 在庫数 個数
500 μg
$170.00
在庫あり
1 mg
$306.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Ganciclovir-d5 is intended for use as an internal standard for the quantification of ganciclovir by GC- or LC-MS. Ganciclovir is a synthetic analog of 2'-deoxy-guanosine that inhibits the replication of human cytomegalovirus (CMV) with an IC50 value of 0.01 μM.1,2 It is effective against strains of CMV from human, monkey, mouse, and guinea pig.1,2 Formulations containing ganciclovir have been used to treat or prevent CMV infections.3,4

1.Rasmussen, L., Chen, P.T., Mullenax, J.G., et al.Inhibition of human cytomegalovirus replication by 9-(1,3-dihydroxy-2-propoxymethyl)guanine alone and in combination with human interferonsAntimicrob. Agents Chemother.26(4)441-445(1984) 2.Freitas, V.R., Smee, D.F., Chernow, M., et al.Activity of 9-(1,3-dihydroxy-2-propoxymethyl)guanine compared with that of acyclovir against human, monkey, and rodent cytomegalovirusesAntimicrob. Agents Chemother.28(2)240-245(1985) 3.Balfour, H.H., Jr.Management of cytomegalovirus disease with antiviral drugsRev.Infect.Dis.12(Suppl. 7)S849-S860(1990) 4.Bean, B.Antiviral therapy: Current concepts and practicesClin.Microbiol.Rev.5(2)146-182(1992)

レビュー

Review for Ganciclovir-d5

Average Rating: 5 ★★★★★ (Based on Reviews and 25 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Ganciclovir-d5

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.